Is OGXI a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

398 people get OGXI articles and Market Currents by email alert.

Get email alerts on OGXI »

HEADLINES:

OncoGenex Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 3
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013

PR Newswire (May 2, 2013)
OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

PR Newswire (May 1, 2013)
OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment

PR Newswire (Apr 30, 2013)
OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013

PR Newswire (Apr 25, 2013)
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

PR Newswire (Apr 23, 2013)
OncoGenex: A Cancer Biotech Worth Betting On
BlackbirdAnalytics • Fri, Apr 12 • 8 Comments
OncoGenex Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer

PR Newswire (Apr 11, 2013)
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

PR Newswire (Mar 28, 2013)
OncoGenex's Second Cancer Drug Gaining Investor Attention
Len Zehr • Tue, Mar 26 • 1 Comment
OncoGenex: SYNERGY Trial Is The Major Catalyst In Sight
Biomed Group • Wed, Mar 13 • 2 Comments
OncoGenex Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012

PR Newswire (Mar 7, 2013)
OncoGenex to Webcast Update on Clinical Development Program and Discussion of Fourth Quarter and Full Year 2012 Financial Results on Thursday, March 7, 2013

PR Newswire (Feb 28, 2013)
OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer

PR Newswire (Feb 12, 2013)
Response Genetics' Competitors: Who To Watch, Who To Worry About
Bay Area Biotech • Fri, Feb 8 • 7 Comments
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences

PR Newswire (Feb 5, 2013)
OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of OGX-427 in combination with Zytiga® in Men with Metastatic Castrate-Resistant Prostate Cancer

PR Newswire (Dec 19, 2012)
Prostate Cancer Market Takes Shape - Part 2: Treatments In Clinical Development
LifeSci Advisors • Thu, Nov 29, 2012 • 3 Comments
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

PR Newswire (Nov 9, 2012)

OncoGenex: A Cancer Biotech Worth Betting On
BlackbirdAnalytics • Fri, Apr 12 • 8 Comments

OncoGenex: A Cancer Biotech Worth Betting On
BlackbirdAnalytics • Fri, Apr 12 • 8 Comments
OncoGenex's Second Cancer Drug Gaining Investor Attention
Len Zehr • Tue, Mar 26 • 1 Comment
OncoGenex: SYNERGY Trial Is The Major Catalyst In Sight
Biomed Group • Wed, Mar 13 • 2 Comments
Playing OncoGenex's ASCO Data
Jessica King Holden • Mon, Jun 4, 2012
OncoGenex Pharmaceuticals: Novel Products, Financial Flexibility
Jason Chew • Wed, Dec 15, 2010

Response Genetics' Competitors: Who To Watch, Who To Worry About
Bay Area Biotech • Fri, Feb 8 • 7 Comments
Prostate Cancer Market Takes Shape - Part 2: Treatments In Clinical Development
LifeSci Advisors • Thu, Nov 29, 2012 • 3 Comments
Trius And OncoGenex Pharmaceuticals: On Their Game
Steven Barnes • Thu, Sep 13, 2012 • 1 Comment
3 Healthcare Stocks With Strong Buy Analyst Ratings And Minimal Debt
ZetaKap • Thu, Aug 23, 2012
5 Pharmaceutical Companies With Insider Buying During August 14-16
Markus Aarnio • Sun, Aug 19, 2012 • 6 Comments
7 Highly Liquid Hedge Fund Stock Picks Undervalued By Target Price
Kapitall • Tue, Aug 14, 2012 • 1 Comment
Micro Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
GuruFundPicks • Wed, Jul 11, 2012 • 9 Comments
3 Pharmaceutical Companies Seeing Insider Buys In Last 30 Days
Markus Aarnio • Tue, Jun 26, 2012 • 4 Comments
Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 5
StockPandit • Mon, May 28, 2012 • 3 Comments
Isis: A Pick To Win The Biotech Derby
Jessica King Holden • Thu, May 10, 2012 • 16 Comments
Tang Capital's Holdings: Insights Into Successful Investing
Scott Matusow • Mon, May 7, 2012 • 11 Comments
Biotech-Focused Star Hedge Fund Tang Capital's Q1 2012 Picks In Its $429 Million Portfolio
GuruFundPicks • Thu, Apr 26, 2012 • 4 Comments
Noteworthy Institutional 5% Ownership Filings This Week In Healthcare Sector
GuruFundPicks • Wed, Apr 11, 2012
Large, Diverse Pipelines At Small Biotech Companies
ScriptVolume • Tue, Mar 13, 2012 • 5 Comments
4 Biotech Stocks Trading At A Steep Discount To Target Price
Kapitall • Sun, Mar 4, 2012 • 5 Comments
14 Rallying Biotech Stocks Being Snapped Up By Insiders
Kapitall • Thu, Feb 2, 2012 • 1 Comment
Keeping An Eye On Isis
Jessica King Holden • Fri, Jan 13, 2012 • 5 Comments
Life Technologies Could Open Doors For Pharmaceuticals
Jessica King Holden • Thu, Jan 12, 2012
Dendreon Rally Justified, But Outstanding Issues May Limit Upside
GuruFundPicks • Mon, Jan 9, 2012 • 6 Comments
Biotech Focused Hedge Fund RA Capital's Top Q3 Picks
GuruFundPicks • Sun, Nov 20, 2011 • 3 Comments

OncoGenex Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 3
OncoGenex Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7
OncoGenex Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012
OncoGenex Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012
OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
Mon, May 10, 2010

OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013

PR Newswire (May 2, 2013)
OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

PR Newswire (May 1, 2013)
OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment

PR Newswire (Apr 30, 2013)
OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013

PR Newswire (Apr 25, 2013)
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

PR Newswire (Apr 23, 2013)
OncoGenex Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer

PR Newswire (Apr 11, 2013)
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

PR Newswire (Mar 28, 2013)
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012

PR Newswire (Mar 7, 2013)
OncoGenex to Webcast Update on Clinical Development Program and Discussion of Fourth Quarter and Full Year 2012 Financial Results on Thursday, March 7, 2013

PR Newswire (Feb 28, 2013)
OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer

PR Newswire (Feb 12, 2013)
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences

PR Newswire (Feb 5, 2013)
Mark Hulbert: Small is beautiful, tiny is even better

at MarketWatch.com (Jan 2, 2013)
OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of OGX-427 in combination with Zytiga® in Men with Metastatic Castrate-Resistant Prostate Cancer

PR Newswire (Dec 19, 2012)
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

PR Newswire (Nov 9, 2012)
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012

PR Newswire (Nov 8, 2012)
OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study

PR Newswire (Nov 6, 2012)
OncoGenex to Webcast Discussion of Third Quarter 2012 Financial Results on Thursday, November 8, 2012

PR Newswire (Oct 30, 2012)
OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer

PR Newswire (Sep 27, 2012)
OncoGenex Pharmaceuticals to Present at Two Upcoming Investor Conferences

PR Newswire (Aug 28, 2012)
OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer

PR Newswire (Aug 7, 2012)

OGXI vs. ETF Alternatives

Company Description

Currently, there's no company description for OGXI.

Sector: Healthcare

Industry: Diagnostic Substances

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, March 7, 5:14 PM OncoGenex Pharmaceuticals (OGXI): Q4 EPS of -$0.28 beats by $0.22. Revenue of $9.8M beats by $2.3M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 12, 1:14 PM OncoGenex Pharmaceuticals (OGXI +1.4%) trades up today after saying it's initiating Phase 2 clinical studies to evalutate OGX-427, a treatment for patients with advanced metastatic bladder cancer. The study is sponsored by Hoosier Oncology Group. Comment! [Healthcare, On the Move]
Monday, February 4, 6:48 PM OncoGenex Pharmaceuticals (OGXI) says that CFO Michelle Burris has resigned that position after she and CEO Scott Cormack told the board last month about a developing personal relationship, which spurred directors to seek a transfer of executive duties. She'll serve as EVP of operations until March 31 and act as a consultant to the firm over the next year; the board tapped Cormack as Principal Financial Officer, Secretary and Treasurer, replacing Burris in those roles. Shares -3.4% AH. Comment! [Healthcare, On the Move]
Friday, March 16, 2012, 9:39 AM OncoGenex Pharmaceuticals (OGXI -18.9%) dives after stating the share offering announced yesterday will involve selling 4.165M shares at a price of just $12. Even after today's crash, OncoGenex shares are changing hands at $14.47. Comment! [Healthcare, On the Move]
Thursday, March 15, 2012, 4:23 PM OncoGenex Pharmaceuticals (OGXI +7.6%) falls 12.3% AH after filing for a stock offering featuring an undisclosed number of shares. The company plans to partly use the proceeds to develop its OGX-427 cancer drug, and possibly other drug candidates. Comment! [Healthcare, On the Move]
Friday, August 5, 2011, 1:33 PM Shares of OncoGeneX (OGXI -24.3%) crater after the firm announces two of its drug-development programs for lung cancer will have delayed results. Interestingly, the share price started falling yesterday in advance of this morning's announcement. 1 Comment [On the Move, Healthcare]
Tuesday, October 19, 2010, 9:15 AM Premarket gainers: CTIC +14%. MEE +10%. PH +9%. RNN +7%.
Losers: INFN -33%. CWTR -29%. OGXI -15%. KCI -13%. BXC -11%. HT -7%. BKCC -7%. NVO -7%. VMW -7%. AIB -6%. ABK -5%. RIO -5%. ALU -5%. AAPL -5%. HL -4%. IBM -4%. RCL -4%. AUY -4%. ARMH -4%. WFT -4%. BHP -4%. SLW -4%. TOT -4%. Comment!
Monday, December 21, 2009, 9:00 AM Premarket gainers: CHTT +33%. TEX +9%. BUCY +8%. INCY +6%. CTIC +5%. BCRX +4%. ABK +4%. AA +4%. CAG +4%.
Losers: OGXI -21%. IRE -9%. GIGM -7%. AIB -6%. LYG -5%. Comment!

ZetaKap
3 Healthcare Stocks With Strong Buy Analyst Ratings And Minimal Debt http://bit.ly/Pe3Lui $CO $LCI $OGXI @ZetaKap
8/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

tooth doc
any thoughts on OGXI share price now after offering..i like the company and prospects...
3/19/12
Reply (1)

• !Report Abuse
View all 1 replies
mdsoneta: I actually bought today @ 13.72. I think the prospect is good and their product is in third phase so reach around 20.00 by next year. GL.
3/19/12
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
Biotech: OncoGeneX (OGXI) Q3-11 Earnings Conference Call Notes http://bit.ly/veJWBZ EXEL
12/15/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Biotech: Archive - Oncogenex (OGXI) Webcast Notes http://bit.ly/vb5Wjz
12/8/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Preferred Research
OGXI, TLB, HT, BKCC overnight offerings.
10/18/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

DeFactoTrader
Pikced up SCLN and ARIA on pullbacks. Might buy some OGXI on a pullback.
3/18/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

tooth doc
any thoughts on OGXI share price now after offering..i like the company and prospects...
3/19/12
Reply (1)

• !Report Abuse
View all 1 replies
mdsoneta: I actually bought today @ 13.72. I think the prospect is good and their product is in third phase so reach around 20.00 by next year. GL.
3/19/12
• !Report Abuse
Add a reply...

140 characters

OGXI OncoGenex Pharmaceuticals Inc.

OGXI

OncoGenex Pharmaceuticals Inc.